

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Determining the efficacy of hand sanitizers against virulent nosocomial infections

Jawad J Najdawi<sup>¶1</sup>, Lester D Hubble<sup>¶1</sup>, Alec J Scarborough<sup>¶1</sup>, Matthew J Watz<sup>¶1</sup>, and Paul  
Watson<sup>¶2\*</sup>

<sup>1</sup> Medical Students, Creighton University School of Medicine, Omaha, Nebraska, United States  
of America

<sup>2</sup>Department of Orthopedics, Creighton University School of Medicine, Omaha, Nebraska,  
United States of America

<sup>#a</sup> Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178

<sup>#b</sup> Department of Orthopedics, Creighton University School of Medicine, 16909 Lakeside Hills  
Ct Suite 208, Omaha, Nebraska, 68130

\*Corresponding Author

Email: [Paul.WatsonMD@alegent.org](mailto:Paul.WatsonMD@alegent.org)

<sup>¶</sup>These authors contributed equally to this work.

## 29 Abstract

30 The goal of this study was to determine the effectiveness of 0.13% benzalkonium  
31 chloride (BAC) (Steiro lotion™), 100% ethanol, and 70% ethyl alcohol (Purell™) hand sanitizer  
32 in subduing the growth of nosocomial bacteria – methicillin resistant *Staphylococcus aureus*  
33 (MRSA), vancomycin resistant *Enterococcus* (VRE), and *Pseudomonas aeruginosa* (*P.*  
34 *aeruginosa*) - when plated on culture media over an extended period of time. In addition, our  
35 objective was to quantify the length of time these hand sanitizer agents remained effective, and  
36 to extrapolate their efficacy in decreasing the transmission of hospital-acquired infections. 50  
37 microliters of either BAC, 100% ethanol, or 70% ethyl alcohol hand gel sanitizer were pipetted  
38 onto Trypticase soy agar with 5% sheep blood plates that were cultured with either MRSA, VRE,  
39 or *P. aeruginosa*. The plates were then incubated at 37.0°C. The zone of inhibition (ZOI) was  
40 measured daily for 5 days and additionally zones were noted whether or not regrowth recurred in  
41 areas where previous growth had initially been inhibited. BAC was found to be superior to both  
42 100% ethanol and 70% ethyl alcohol in the inhibition of MRSA over all time points (p values  
43 < .05). BAC was found to be superior to 70% ethyl alcohol in the inhibition of VRE over all time  
44 points (p values < .05), but not statistically superior to 100% ethanol against the inhibition of  
45 VRE over any time points. BAC was found to be superior to 70% ethyl alcohol and 100%  
46 ethanol in the inhibition of pseudomonas over 72 and 24 hours, respectively (p values < .05). The  
47 results of this study demonstrate *in vitro* efficacy of BAC of preventing regrowth of common  
48 nosocomial bacteria over a prolonged period of time, especially when compared to ethyl alcohol.  
49 Further study is warranted to determine *in vivo* effectiveness of this formulation of BAC as well  
50 as the appropriate time frame of application for effectiveness against *P. aeruginosa*.

51

## 52 Introduction

53 Hospital-acquired or healthcare-associated infections (HAIs) are the most common  
54 complication in hospitalized patients [1]. They occur with an estimated incidence of 4.5 HAIs  
55 per 100 hospital admissions, and amount to an additional burden of \$35 to \$45 billion dollars on  
56 the healthcare system [2]. They are responsible for significant hardship accounting for more than  
57 90,000 deaths each year, putting HAIs among the top 5 leading causes of death in the United  
58 States [3-5]. Transmission of pathogens from healthcare staff serves as an important source of  
59 HAIs. Personal hygiene is a crucial aspect of reducing transmission, and hand washing, or  
60 sanitizing is required with every patient contact [6].

61

62 Both alcohol-based and alcohol-free hand sanitizers are available options when hand  
63 washing is not available or efficient. Alcohol-based sanitizers containing 60-95% alcohol are  
64 most often used in hospitals. Benzalkonium chloride (BAC) is the active ingredient contained in  
65 most alcohol-free hand sanitizer products available today. It has been theorized that BAC  
66 possesses an extended killing time of bacteria when the solution has dried compared to alcohol-  
67 based agents [7-10].

68

69 The goal of this study was to determine the duration of efficacy of .13% BAC, 70% ethyl  
70 alcohol, and 100% ethanol in decreasing methicillin-resistant *Staphylococcus aureus* (MRSA),  
71 vancomycin-resistant *Enterococcus* (VRE), and *Pseudomonas aeruginosa* (*P. aeruginosa*)  
72 colonization and regrowth over an extended period of time when plated on culture media.

73

## 74 **Materials and Methods**

75 BD BBL™ Trypticase™ soy agar slants prepared media of nosocomial bacteria MRSA,  
76 VRE, and *P. aeruginosa* were grown on agar plates for 24 hours at 37 degrees Celsius and used  
77 to establish a reservoir.

78  
79 A 0.5 McFarland standard solution was created for the MRSA, VRE, and *P. aeruginosa*  
80 bacteria strains, by using a calibrated inoculating loop to transfer bacteria from the incubated  
81 blood agar plates to a vial of saline with 0% absorbance until the absorbance of the vial solution  
82 was between 0.08 and 0.1%.

83  
84 A bacteria lawn was created by using a cotton applicator to evenly distribute an aliquot of  
85 the 0.5 McFarland standard MRSA solution across the surface of Trypticase™ soy agar with 5%  
86 sheep blood plates. This process was repeated using the 0.5 Mcfarland standard for MRSA,  
87 VRE, and *P. aeruginosa* solutions until eight bacteria lawns of each solution were created.

88  
89 50 microliters of 0.13% benzalkonium chloride (BAC) (Steiro lotion™, Germcure, Houma  
90 Louisiana), 100% ethanol (Sigma-Aldrich Inc., St. Louis, Missouri) and ethyl alcohol 70%  
91 (Purell™, Gojo, Akron, Ohio) solution were pipetted onto each of the eight 5% sheep blood agar  
92 plates. Reverse pipetting was used to ensure accurate amounts of viscous solution were pipetted  
93 onto the plates. Plates were left for one hour to dry.

94  
95 The MRSA, VRE, and *P. aeruginosa* inoculated plates were incubated at 37 degrees  
96 Celsius overnight. They were all grown in aerobic conditions. The plates were removed from the  
97 incubator every 24 hours for a growth period of 120 hours to take photographs and quantitative  
98 measurements of the zone of inhibition (ZOI) of each antiseptic. Measurements were performed  
99 for a total of 120 hours for the MRSA, VRE, and *P. aeruginosa* plates.

100  
101 One methodology was utilized to perform quantitative measurements of the ZOI for each  
102 antiseptic. The methodology used to perform digital measurements of the ZOI was the free  
103 internet software program, ImageJ. ImageJ utilizes the pixels of the digital photographs taken  
104 and the known standard diameters of the agar plates to quantitatively measure the ZOI. Four  
105 researchers made the digital measurements independently to increase validity of the  
106 measurements.

107  
108 Statistical analysis was performed by measuring the difference in area of inhibition  
109 between ethyl alcohol, ethanol, and benzalkonium chloride for *P. aeruginosa*, VRE, and MRSA  
110 each. P-values were obtained using t-tests comparing each solution independently.

## 111 **Results**

112  
113 Ethyl alcohol and Ethanol showed significant regrowth of bacteria within 24 hours  
114 against *P. aeruginosa*, VRE, and MRSA (Figs 1-3). This regrowth of bacteria continued the full  
115 5 days, or 120 hours, that the study was conducted. BAC showed regrowth of only *P. aeruginosa*  
116 after the initial 24-hour period had passed. For BAC, no regrowth was noted throughout the 120  
117 hours in MRSA or VRE after the initial ZOI had been established (Figs 1 and 2, 4 and 5).

118

119 **Fig 1. One MRSA plate after 24 hours in incubator.** Ethyl alcohol (top left), Ethanol  
 120 (top right), and BAC (bottom).

121 **Fig 2. One VRE plate after 24 hours in incubator.** Ethyl alcohol (top left), Ethanol (top  
 122 right), and BAC (bottom).

123 **Fig 3. One *P. aeruginosa* plate after 24 hours in incubator.** Ethyl alcohol (top left),  
 124 Ethanol (top right), and BAC (bottom).

125 **Fig 4. Same MRSA plate after 120 hours in incubator.** Ethyl alcohol (top left),  
 126 Ethanol (top right), and BAC (bottom).

127 **Fig 5. Same VRE plate after 120 hours in incubator.** Ethyl alcohol (top left), Ethanol  
 128 (top right), and BAC (bottom).

129  
 130 For *P. aeruginosa*, BAC showed larger zones of inhibition on day 2, 3 and 5, but ethanol  
 131 showed larger zones of inhibition on days 1 and 4. This is shown in Table 1. Aside from days 1  
 132 and 4 of pseudomonas, Table 1, Ethyl alcohol did not demonstrate a clear zone of inhibition for  
 133 any other plates and thus was labeled as 0 due to significant regrowth of bacteria beginning at 24  
 134 hours and lasting the full 120 hours (Figures 1-6). Overall, BAC showed larger zones of  
 135 inhibition compared to ethanol and ethyl alcohol for VRE and MRSA. This is demonstrated in  
 136 Tables 2 and 3.

137

138 **Table 1. Growth of *P. aeruginosa* vs Ethyl alcohol, Ethanol, and BAC with associated p-**  
 139 **values. Values denote the zone of inhibition measured in centimeters.**

	<b>Ethyl alcohol (cm<sup>2</sup>)</b>	<b>Ethanol (cm<sup>2</sup>)</b>	<b>BAC (cm<sup>2</sup>)</b>	<b>Ethyl alcohol vs. Ethanol</b>	<b>Ethanol vs. BAC</b>	<b>Ethyl alcohol vs. BAC</b>
				P-value	P-value	P-value
<b>Initial Zone</b>	5.921	7.078	3.647	0.0388	0.00630	0.0452
<b>Day 1</b>	0.401	2.72	1.971	2.74e <sup>-5</sup>	0.00330	0.000200
<b>Day 2</b>	0	0.694	0.820	0.00720	0.0609	7.39e <sup>-7</sup>
<b>Day 3</b>	0	0.302	0.405	0.0572	0.0572	0.00130
<b>Day 4</b>	0	0.177	0.153	0.0929	0.7186	0.0557
<b>Day 5</b>	0	0.143	0.162	0.0846	1	0.0846

140  
141  
142  
143

**Table 2. Growth of VRE vs Ethyl alcohol, Ethanol, and BAC with associated p-values. Values denote the zone of inhibition measured in centimeters.**

	<b>Ethyl alcohol (cm<sup>2</sup>)</b>	<b>Ethanol (cm<sup>2</sup>)</b>	<b>BAC (cm<sup>2</sup>)</b>	<b>Ethyl alcohol vs. Ethanol</b>	<b>Ethanol vs. BAC</b>	<b>Ethyl alcohol vs. BAC</b>
				P-value	P-value	P-value
<b>Initial Zone</b>	6.161	9.846	5.359	7.50e <sup>-6</sup>	1	7.50E-06
<b>Day 1</b>	0	4.894	5.494	8.25e <sup>-12</sup>	0.197	6.43e <sup>-10</sup>
<b>Day 2</b>	0	4.666	5.255	1.91e <sup>-12</sup>	0.165	4.28e <sup>-10</sup>
<b>Day 3</b>	0	4.582	4.961	3.39e <sup>-11</sup>	0.362	2.68e <sup>-10</sup>
<b>Day 4</b>	0	4.645	4.894	4.13e <sup>-11</sup>	0.585	2.08e <sup>-9</sup>
<b>Day 5</b>	0	4.623	4.952	9.89e <sup>-10</sup>	0.486	4.38e <sup>-10</sup>

144  
145  
146  
147

**Table 3. Growth of MRSA vs Ethyl alcohol, Ethanol, and BAC with associated p-values. Values denote the zone of inhibition measured in centimeters.**

	<b>Ethyl alcohol (cm<sup>2</sup>)</b>	<b>Ethanol (cm<sup>2</sup>)</b>	<b>BAC (cm<sup>2</sup>)</b>	<b>Ethyl alcohol vs. Ethanol</b>	<b>Ethanol vs. BAC</b>	<b>Ethyl alcohol vs. BAC</b>
				P-value	P-value	P-value
<b>Initial Zone</b>	1.785	4.035	5.396	9.56e <sup>-8</sup>	2.41e <sup>-5</sup>	6.49e <sup>-11</sup>
<b>Day 1</b>	0	3.477	5.338	1.0426e <sup>-11</sup>	3.33e <sup>-8</sup>	6.38 <sup>-17</sup>

<b>Day 2</b>	0	3.341	5.289	5.184e <sup>-12</sup>	4.61e <sup>-8</sup>	6.65e <sup>-18</sup>
<b>Day 3</b>	0	3.272	5.293	2.950e <sup>-12</sup>	1.70e <sup>-8</sup>	7.71e <sup>-18</sup>
<b>Day 4</b>	0	3.27	5.169	7.286e <sup>-12</sup>	4.73e <sup>-8</sup>	2.01e <sup>-18</sup>
<b>Day 5</b>	0	3.151	5.09	3.015e <sup>-11</sup>	6.69e <sup>-8</sup>	1.71e <sup>-18</sup>

148

149

**Fig 6. Same *P. aeruginosa* plate after 120 hours in incubator.** Ethyl alcohol (top left), Ethanol (top right), and BAC (bottom).

150

151

152

153

154

155

156

157

158

159

160

161

162

**Fig 7. Percent of the initial zone of inhibition remaining against MRSA for each subsequent day vs Ethyl alcohol, ethanol and BAC.**

163

164

**Fig 8. Percent of the initial zone of inhibition remaining against VRE for each subsequent day vs Ethyl alcohol, ethanol and BAC.**

165

166

167

168

**Fig 9. Percent of the initial zone of inhibition remaining against *P. aeruginosa* for each subsequent day vs Ethyl alcohol, ethanol and BAC.**

169

170

**Discussion**

171

172

173

174

175

176

177

178

179

180

181

182

The overlying goal of this study was to test the effectiveness and duration of effect of hand sanitizers that could be used in the healthcare setting to potentially decrease the incidence of HAIs. This study demonstrates the anti-microbial activity of alcohol-based hand sanitizing agents (70% ethyl alcohol and 100% ethanol) and alcohol-free agents (BAC) against common virulent antibiotic-resistant micro-organisms MRSA, VRE, and *P. aeruginosa* in vitro over a



183 period of 120 hours. The 0.13% BAC formulation used here exhibited superior effectiveness and  
184 duration when compared to 70% ethyl alcohol and 100% ethanol against all three micro-  
185 organisms used in this study. Specifically, against MRSA and VRE, BAC created clear cut zones  
186 of inhibition (ZOI) with minimal bacterial regrowth over a period of 120 hours. Against *P.*  
187 *aeruginosa*, BAC created a clear cut ZOI up to 24 hours before allowing some bacterial regrowth  
188 to occur on a few plates after the 24-hour mark, and eventually all plates after the 96-hour mark.  
189 These results are in stark contrast to the efficacy of the commonly used alcohol-based hand  
190 sanitizing agent 70% ethyl alcohol, which failed to prevent bacterial regrowth for any micro-  
191 organism. Even at the 24-hour mark no clear cut ZOI could be appreciated on any plate.  
192 Likewise, 100% ethanol also failed to prevent bacterial regrowth for any of the micro-organisms  
193 used. BAC not only proved efficacious in preventing the regrowth of bacteria over an extended  
194 period of time, but against MRSA and VRE also demonstrated an ability to maintain the integrity  
195 of the ZOI once initially established, in regard to size, over the course of 120 hours. Against *P.*  
196 *aeruginosa*, the ZOI created by BAC was noted to shrink in size over the duration of the  
197 experiment.

198  
199 When measuring the difference in area of inhibition between each hand sanitizing agent  
200 against each bacterium, BAC proved to be most efficacious in subduing the growth of MRSA  
201 over all time points with statistically significant results (Table 3). BAC was also statistically  
202 more efficacious when compared to 70% ethyl alcohol over all time points against VRE (Table  
203 2), and over the course of the first 72 hours against pseudomonas (Table 1). Our results showed  
204 that BAC was more efficacious against *P. aeruginosa* over the course of the first 24 hours when  
205 compared to 100% ethanol, but no significant difference was found between BAC and 100%  
206 ethanol against VRE over any time points. However, the use of 100% ethanol is unlikely as a  
207 hand sanitizing agent in the clinical setting. These results suggest that BAC could be used over  
208 70% ethyl alcohol as a hand sanitizing agent that could provide an extended action of effective  
209 anti-microbial protection and reduce the number of HAIs spread from patient to patient by  
210 healthcare workers.

211  
212 Benzalkonium chloride is commonly used in the healthcare setting as a bactericidal agent  
213 in surface disinfectants, nasal sprays, and eye drops with minimal skin irritation. The mechanism  
214 of action of BAC is related to its ability to penetrate the bacterial cell wall that leads to damage  
215 and loss of cell membrane integrity. This leads to leakage of molecular components, and  
216 eventual cell wall lysis [10]. Alcohol's antimicrobial effect stems from its ability to denature  
217 proteins. Concentrations between 60-95% are most effective with higher concentrations losing  
218 potency because of the necessity to have water with the alcohol to be most effective [10].  
219 Alcohol is effective at killing microbes present on the skin but has no lasting effect. BAC is non-  
220 volatile and therefore is able to remain on the skin while it dries [13]. This explains the length of  
221 duration of BACs anti-microbial effectiveness observed in our experiment. To our knowledge,  
222 the efficacy of BAC against MRSA, VRE, and *P. aeruginosa* in comparison to alcohol-based  
223 hand sanitizing agents had not been previously investigated. As such, this is the first study to  
224 demonstrate a superior ability of BAC compared to alcohol-based hand sanitizers in preventing  
225 *in vitro* MRSA, VRE, and Pseudomonas regrowth following application. Further work is  
226 necessary to determine whether BAC exhibits similar effectiveness *in vivo*.

227

228 This study has several important limitations. First, these agents were tested against  
229 microbial cultures of MRSA, VRE, and *P. aeruginosa*. It remains to be seen whether similar  
230 efficacy will be shown against these pathogens when used as a topical agent *in vivo*. Second,  
231 although the BAC formulation used in this study demonstrated a bactericidal effect the results  
232 may be variable depending on the particular strain of bacteria isolated, as modes of resistance  
233 may vary greatly between strains. Thirdly, our relatively small sample of eight bacterial plates  
234 could be the reason BAC did not show a statistical significance when compared to 100% ethanol  
235 against VRE. It remains to be seen whether a larger sample size would ultimately show that BAC  
236 is more efficacious against VRE when compared to 100% ethanol.  
237

## 238 **Conclusion**

239 In conclusion, BAC was shown to be superior to both 100% ethanol and 70% ethyl  
240 alcohol hand sanitizer in subduing the growth of MRSA over the course of five days. BAC was  
241 also shown to be superior when compared to 70% ethyl alcohol in subduing the growth of VRE  
242 over the course of five days, and pseudomonas over the course of 72 hours. BAC was shown to  
243 be superior to 100% ethanol in subduing the growth of *P. aeruginosa* over the course of 24  
244 hours, but no statistically significant difference was noted over 100% ethanol against VRE. BAC  
245 was able to maintain the ZOI for VRE and MRSA throughout the course of the 5 days, whereas  
246 for *P. aeruginosa*, regrowth was observed after 24 hours. Although there was regrowth seen with  
247 BAC, it was still significantly less than the bacterial regrowth observed for 70% ethyl alcohol  
248 and 100% ethanol. The results of this study demonstrate the potential for using BAC as an  
249 effective hand sanitizer in the healthcare setting given the duration of its effect and its greater  
250 ability to potentially prevent the spread of common nosocomial infections. Further study is  
251 warranted to determine *in vivo* effectiveness of this formulation of BAC as well as the  
252 appropriate time frame of application for effectiveness against HAIs.  
253



## 254 **References**

- 255
- 256 1. Burke JP. Infection control-a problem for patient safety. *N Engl J Med* 2003;348(7):651-656.
- 257 2. Scott RD. The direct medical costs of healthcare-associated infections in US hospitals and the
- 258 benefits of prevention. 2009.
- 259 3. Leape LL, Berwick DM. Five years after To Err Is Human: what have we learned? *JAMA*
- 260 2005;293(19):2384-2390.
- 261 4. Klevens RM, Edwards JR, Richards Jr CL, Horan TC, Gaynes RP, Pollock DA, et al.
- 262 Estimating health care-associated infections and deaths in US hospitals, 2002. *Public Health Rep*
- 263 2007;122(2):160-166.
- 264 5. Anderson RN. Deaths: leading causes for 1999. 2001.
- 265 6. Khan HA, Baig FK, Mehboob R. Nosocomial infections: Epidemiology, prevention, control
- 266 and surveillance. *Asian Pacific Journal of Tropical Biomedicine* 2017;7(5):478-482.
- 267 7. Gold NA, Avva U. Alcohol Sanitizer. StatPearls Publishing. 2020.
- 268 8. Cooper RA. Surgical site infections: epidemiology and microbiological aspects in trauma and
- 269 orthopaedic surgery. *International wound journal* 2013;10(s1):3-8.
- 270 9. Anderson DJ, Kaye KS, Chen LF, Schmader KE, Choi Y, Sloane R, et al. Clinical and
- 271 financial outcomes due to methicillin resistant *Staphylococcus aureus* surgical site infection: a
- 272 multi-center matched outcomes study. *PloS one* 2009;4(12):e8305.
- 273 10. Bondurant S, McKinney T, Bondurant L, Fitzpatrick L. Evaluation of a benzalkonium
- 274 chloride hand sanitizer in reducing transient *Staphylococcus aureus* bacterial skin contamination
- 275 in health care workers. *Am J Infect Control* 2020;48(5):522-526.
- 276 11. Khan HA, Ahmad A, Mehboob R. Nosocomial infections and their control strategies. *Asian*
- 277 *pacific journal of tropical biomedicine* 2015;5(7):509-514.
- 278 12. De Lissovoy G, Fraeman K, Hutchins V, Murphy D, Song D, Vaughn BB. Surgical site
- 279 infection: incidence and impact on hospital utilization and treatment costs. *Am J Infect Control*
- 280 2009;37(5):387-397.
- 281 13. Bondurant SW, Duley CM, Harbell JW. Demonstrating the persistent antibacterial efficacy
- 282 of a hand sanitizer containing benzalkonium chloride on human skin at 1, 2, and 4 hours after
- 283 application. *Am J Infect Control* 2019;47(8):928-932.

284



Figure 1



Figure 2



Figure 3



Figure 4



Figure 5



Figure 6



% ZOI Remaining Against MRSA




Figure 7

% ZOI Remaining Against VRE




Figure 8

% ZOI Remaining Against Pseudomonas




Figure 9